Celyad Oncology SA
CYAD | BR
Overview
Corporate Details
- ISIN(s):
- BE0974260896 (+2 more)
- LEI:
- 549300ORR0M8XF56OI64
- Country:
- Belgium
- Address:
- RUE ANDRE DUMONT 9, 1435 MONT-SAINT-GUIBERT
- Website:
- https://celyad.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Celyad Oncology is a biotechnology company focused on the research and discovery of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Chat, Summarize & Extract with AI!
You have of free filing views remaining.
Upgrade for unlimited access.
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2024-09-16 00:00 |
Board/Management Information
20240916_CYAD_PR_new-CEO-ENG (1).pdf
|
English | 85.6 KB | |
| 2024-09-16 00:00 |
Board/Management Information
20240916_CYAD_PR_new-CEO-FR (1).pdf
|
French | 93.8 KB | |
| 2024-09-15 14:00 |
Interim Report
06082024_Celyad - Financial Report H1-2024 - EN.pdf
|
English | 852.9 KB | |
| 2024-09-15 14:00 |
Interim Report
Celyad Oncology - RAPPORT FINANCIER INTERMEDIAIRE_2024 - FR.pdf
|
French | 1.2 MB | |
| 2024-05-06 19:00 |
Share Issue/Capital Change
AGEx Ceyad Oncology 6 mai 2024 - signatures digitales.pdf
|
French | 2.5 MB | |
| 2024-05-06 18:00 |
Post-Annual General Meeting Information
PV AGO Ceyad Oncology 6 mai 2024 - signé - FR.pdf
|
French | 1.4 MB | |
| 2024-04-05 08:00 |
Pre-Annual General Meeting Information
CELYAD-AGO-et-AGE-mai-2024-Informations-aux-actionnaires-FR.Final_.pdf
|
French | 118.8 KB | |
| 2024-04-05 08:00 |
Legal Proceedings Report
Rapport_Special_CA_pour_AGE_Sonnette_dalarme_-_2024_-_FR.signed.pdf
|
French | 294.9 KB | |
| 2024-04-05 08:00 |
Registration Form
Celyad-Oncology-coord.-ENG-06.05.2024.pdf
|
English | 361.3 KB | |
| 2024-04-05 08:00 |
Registration Form
Celyad-Oncology-coord.-FR-06.05.2024.pdf
|
French | 225.1 KB | |
| 2024-04-05 08:00 |
Share Issue/Capital Change
Warrant-Plan-2024-ENG.final_.pdf
|
English | 208.7 KB | |
| 2024-04-05 08:00 |
Remuneration Information
Warrant-Plan-2024-FR.final_.pdf
|
French | 258.5 KB | |
| 2024-04-05 08:00 |
Pre-Annual General Meeting Information
CELYAD-AGM-EGM-May-2024-Information-to-shareholders-ENG.Final_.pdf
|
English | 122.4 KB | |
| 2024-04-05 08:00 |
Proxy Solicitation & Information Statement
CELYAD-AGO-et-AGE-mai-2024-Procuration-personnes-physiques-FR-ENG.pdf
|
French | 469.6 KB | |
| 2024-04-05 08:00 |
Pre-Annual General Meeting Information
Special_Report_Board_to_AGEX_Alarm_bell_2024_-_ENG.signed.pdf
|
English | 329.9 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-11-28 | Kane Matthew | Board | Other | 1,035,714 | 279,642.78 EUR |
| 2024-11-26 | Piscitelli Dominic | Board | Other | 10,000 | 2,700.00 EUR |
| 2024-11-25 | Iserentant Hannes | Executive member | Other | 30,000 | 8,100.00 EUR |
| 2024-11-22 | Phan An | Executive member | Other | 30,000 | 8,100.00 EUR |
| 2024-11-06 | Goblet Serge | Board | Other | 10,000 | 2,700.00 EUR |
| 2024-11-05 | Udier Blagovic Marina | Board | Other | 10,000 | 2,700.00 EUR |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
ANIMALCARE GROUP PLC | United Kingdom | ANCR | |
|
Annexin Pharmaceuticals AB | Sweden | ANNX | |
|
Apontis Pharma AG | Germany | APPH | |
|
Aptahem AB | Sweden | APTA | |
|
Arctic Bioscience | Norway | ABS | |
|
ArcticZymes Technologies | Norway | AZT | |
|
argenx SE | Netherlands (Kingdom of the) | 1AE | |
|
ARIX BIOSCIENCE PLC | United Kingdom | ARIX | |
|
AroCell AB | Sweden | AROC | |
|
Arterra Bioscience | Italy | ABS |